Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity

Arico-Muendel, Christopher C. ; Belanger, Bruce ; Benjamin, Dennis ; Blanchette, Heather S. ; Caiazzo, Teresa M. ; Centrella, Paolo A. ; DeLorey, Jennifer ; Doyle, Elisabeth G. ; Gradhand, Ulrike ; Griffin, Sarah T. ; Hill, Susan ; Labenski, Matthew T. ; Morgan, Barry A. ; O'Donovan, Gary ; Prasad, Kavirayani ; Skinner, Steven ; Taghizadeh, Nazbeh ; Thompson, Charles D. ; Wakefield, James ; Westlin, William ; White, Kerry F. (2013) Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity Drug Metabolism and Disposition, 41 (4). pp. 814-826. ISSN 0090-9556

Full text not available from this repository.

Official URL:

Related URL:


The natural product fumagillin exhibits potent antiproliferative and antiangiogenic properties. The semisynthetic analog PPI-2458, [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-[(2R)-1-amino-3-methyl-1-oxobutan-2-yl]carbamate, demonstrates rapid inactivation of its molecular target, methionine aminopeptidase-2 (MetAP2), and good efficacy in several rodent models of cancer and inflammation with oral dosing despite low apparent oral bioavailability. To probe the basis of its in vivo efficacy, the metabolism of PPI-2458 was studied in detail. Reaction phenotyping identified CYP3A4/5 as the major source of metabolism in humans. Six metabolites were isolated from liver microsomes and characterized by mass spectrometry and nuclear resonance spectroscopy, and their structures were confirmed by chemical synthesis. The synthetic metabolites showed correlated inhibition of MetAP2 enzymatic activity and vascular endothelial cell growth. In an ex vivo experiment, MetAP2 inhibition in white blood cells, thymus, and lymph nodes in rats after single dosing with PPI-2458 and the isolated metabolites was found to correlate with the in vitro activity of the individual species. In a phase 1 clinical study, PPI-2458 was administered to patients with non-Hodgkin lymphoma. At 15 mg administered orally every other day, MetAP2 in whole blood was 80% inactivated for up to 48 hours, although the exposure of the parent compound was only ∼10% that of the summed cytochrome P450 metabolites. Taken together, the data confirm the participation of active metabolites in the in vivo efficacy of PPI-2458. The structures define a metabolic pathway for PPI-2458 that is distinct from that of TNP-470 ([(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate). The high level of MetAP2 inhibition achieved in vivo supports the value of fumagillin-derived therapeutics for angiogenic diseases.

Item Type:Article
Source:Copyright of this article belongs to American Society for Pharmacology and Experimental Therapeutics.
ID Code:105680
Deposited On:21 Dec 2017 12:01
Last Modified:21 Dec 2017 12:01

Repository Staff Only: item control page